04Mar 2019

USEFULNESS OF SERUM PROCALCITONIN AS A PREDICTOR BIOMARKER OF ATHEROSCLEROSIS IN DIALYSIS PATIENTS.

  • Department of Internal Medicine, BEU,Turkey.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background:The most common cause of death among the patients with end-stage renal disease is coronary artery disease. It is known that inflammation plays a key role in coronary artery disease. The aim of this study was to determine the relationship between serum procalcitonin levels and atherosclerosis among dialysis patients. Material and Method: A total of consecutive 74dialysispatients (mean age: 54.92?13.9 years and male/female: 47/27) were included in this study. All participants were divided into two groups according to presence of atherosclerosis.We have planned to compare the patients on hemodialysis (HD) and peritoneal dialysis (PD) each other considering the parameters of inflammation in particular serum procalcitonin (PCT) and C-reactive protein (CRP) with atherosclerosis. Univariate and multivariate statistical methods were used by using SPSS packet programme. Results:The mean of ages of HD and PD patients were 59.3?11.3 and 50.7?14.9 years respectively. The levels of PCT were higher among atherosclerotic dialysis patients (p<0.001 and p=0.036, respectively). Considering the patients on hemodialysis, there were significant correlation between CRP and PCT. However this significant correlation was not observed among the patients on PD despite they had increased levels of CRP and PCT (p<0.001, r=0.62 and p=0.362, r=-0.16, respectively). Conclusion:Combining PCT and CRP levels could be a reliable marker of chronic inflammation that is associated with atherosclerosis in dialysis patients.

  1. Sezer S, Ozdemir FN, Arat Z, Turan M, Haberal M. Triad of malnutrition, inflammation, and atherosclerosis in hemodialysis patients. Nephron. 2002 Jul;91(3):456-62.
  2. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant. 2002 Mar;17(3):435-41.
  3. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992 Apr 11;339(8798):883-7.
  4. Valente AJ, Rozek MM, Sprague EA, Schwartz CJ. Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation. 1992 Dec;86(6 Suppl):III20-5.
  5. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000 Apr;35(4 Suppl 1):S117-31.
  6. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987 Apr;31(4):973-80.
  7. Bergstr?m JHO, Heimb?rger O, Lindholm B, Qureshi Ar. Elevated serum c reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am SocNephrol 1995; 6:573.
  8. Lobbodez T, Pujo M, el Haggan W, Hurault de LignyB,Levaltier B, Ryckelynck JP. Prevention of malnutrition in peritoneal dialysis patients. Nephrologie. 2003;24(7):387-9.
  9. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 Feb;55(2):648-58.
  10. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999 May;55(5):1899-911.
  11. Stenvinkel P, Heimb?rger O, Wang T, Elinder C-G, Bergstr?m J, Lindholm B. A syndrome of malnutrition, inflammation and atherosclerosis (MIA) is associated with elevated serum hyaluronan and increased mortality in chronic renal failure (CRF). J Am Soc Nephrol1999; 10: 182A
  12. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int. 1999 May;55(5):1945-51.
  13. Keane WF, Collins AJ. Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis. 1994 Dec;24(6):1010-8.
  14. Devereux RB. Method of recognition and assesment of left ventricular hypertrophy. Medicographia 1995;17:12.
  15. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004 Jun;65(6):2380-9.
  16. Plata-Salaman CR. Cytokines and anorexia: a brief overview. SeminOncol. 1998 Feb;25(1 Suppl 1):64-72.
  17. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991 May;39(5):954-60.
  18. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994 Mar;45(3):890-6.
  19. Pereira BJ, Poutsiaka DD, King AJ, Strom JA, Narayan G, Levey AS, et al. In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int. 1992 Dec;42(6):1419-24.
  20. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998 Jul;32(1):107-14.
  21. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl. 2002 May(80):99-102.
  22. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am SocNephrol. 2003 Jul;14(7):1871-9.
  23. Visvardis G, Griveas I, Fleva A, Giannakou A, Papadopoulou D, Mitsopoulos E, et al. Relevance of procalcitonin levels in comparison to other markers of inflammation in hemodialysis patients. Ren Fail. 2005;27(4):429-34.
  24. Chauveau P, Level C, Lasseur C, Bonarek H, Peuchant E, Montaudon D, et al. C-reactive protein and procalcitonin as markers of mortality in hemodialysis patients: a 2-year prospective study. J RenNutr. 2003 Apr;13(2):137-43.
  25. Guz G, Colak B, Hizel K, Reis KA, Erten Y, Bali M, et al. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. Perit Dial Int. 2006 Mar-Apr;26(2):240-8.
 

[Muammer Bilici and Eyup Kulah. (2019); USEFULNESS OF SERUM PROCALCITONIN AS A PREDICTOR BIOMARKER OF ATHEROSCLEROSIS IN DIALYSIS PATIENTS. Int. J. of Adv. Res. 7 (Mar). 315-319] (ISSN 2320-5407). www.journalijar.com

Muammer Bilici
Bulent Ecevit University

DOI:

Article DOI: 10.21474/IJAR01/8637      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8637

Download Full Paper

Download PDF No. of Downloads: 21 | No. of Views: 98